earnings

2 Reasons Exact Sciences Investors Shouldn't Worry -- and 1 Reason They Should
2 Reasons Exact Sciences Investors Shouldn't Worry -- and 1 Reason They Should
Motley Fool
EXACT Sciences
earnings
Cologuard
Flag link:
Will Valeant Pharmaceuticals' Turnaround Fizzle with Its Q4 Results?
Will Valeant Pharmaceuticals' Turnaround Fizzle with Its Q4 Results?
Motley Fool
Valeant Pharmaceuticals
earnings
Flag link:
bluebird bio Updates Plans for the Year Ahead
bluebird bio Updates Plans for the Year Ahead
Motley Fool
Bluebird Bio
earnings
Flag link:
Momenta Pharmaceuticals Wraps Up a Bleak Year
Momenta Pharmaceuticals Wraps Up a Bleak Year
Motley Fool
Momenta Pharmaceuticals
earnings
biosimilars
generics
Flag link:
MiMedx shares tumble on internal accounting investigation, delayed 2017 earnings
MiMedx shares tumble on internal accounting investigation, delayed 2017 earnings
Drug Delivery Business News
MiMedx
accounting
earnings
devices
Flag link:
Medtronic’s Q3 beats expectations
Medtronic’s Q3 beats expectations
Mass Device
Medtronic
earnings
devices
Flag link:
Acorda posts Q4 revenue beat, but misses EPS estimates
Acorda posts Q4 revenue beat, but misses EPS estimates
Drug Delivery Business News
Acorda Therapeutics
earnings
Flag link:
Gilead Sciences: Investors Are Betting On A Better 2019
Gilead Sciences: Investors Are Betting On A Better 2019
Forbes
Gilead Sciences
earnings
Flag link:
Sales for Sanofi’s U.S. diabetes biz fall -30% in Q4
Sales for Sanofi’s U.S. diabetes biz fall -30% in Q4
Drug Delivery Business News
Sanofi
earnings
diabetes
Flag link:
Novo Nordisk's Dichotomy Abounds
Novo Nordisk's Dichotomy Abounds
Motley Fool
Novo Nordisk
diabetes
earnings
Flag link:
Allergan's Pipeline Matters More Than Its Earnings Do: RBC
Allergan's Pipeline Matters More Than Its Earnings Do: RBC
TheStreet.com
Allergan
earnings
Flag link:
Biopharma in charts: Key takeaways from Q4 earnings
Biopharma in charts: Key takeaways from Q4 earnings
Biopharma Dive
earnings
Merck
JNJ
AbbVie
Roche
Celgene
Eli Lilly
Flag link:
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Marketwatch
Bristol-Myers Squibb
earnings
Opdivo
Yervoy
advanced lung cancer
Flag link:
What to Expect With Gilead Sciences' Q4 Results
What to Expect With Gilead Sciences' Q4 Results
Motley Fool
Gilead Sciences
earnings
Flag link:
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
Motley Fool
Amgen
earnings
Flag link:
3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock
3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock
Motley Fool
Merck
earnings
diabetes
cardiovascular disease
vaccines
Flag link:
Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls
Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls
TheStreet.com
pharma execs
M&A
earnings
drug pricing
Pfizer
Ian Read
Merck
Ken Frazier
Enrique Conterno
Eli Lilly
Flag link:
AstraZeneca pins its hopes on China
AstraZeneca pins its hopes on China
Biopharma Dive
China
AstraZeneca
earnings
Flag link:
Merck quarterly profit beats on Keytruda demand
Merck quarterly profit beats on Keytruda demand
Yahoo/Reuters
Merck
earnings
Keytruda
Flag link:
Amgen reports profit below analyst views, but beats expectations on earnings outlook
Amgen reports profit below analyst views, but beats expectations on earnings outlook
CNBC
Amgen
earnings
Flag link:

Pages